Can two immune boosters beat advanced melanoma?

NCT ID NCT01024231

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining two immunotherapy drugs, nivolumab and ipilimumab, can safely treat advanced melanoma that cannot be removed by surgery. The study includes adults with stage III or IV melanoma and focuses on the safety and tolerability of the drug combination, given either at the same time or in sequence. Researchers will also look at how well the tumors respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab (BMS-936558) combined with ipilimumab
What this could lead to: If this combination proves safe and effective, it could offer a new treatment option for advanced melanoma, potentially improving response rates and survival.
What could go wrong: This is an early-phase trial, so the combination may not work as hoped or could cause significant side effects. The results will need confirmation in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT MELANOMA

Contacts and locations

Locations

Hillman Cancer Research Pavilion

Pittsburgh, Pennsylvania, 15232, United States
Medstar Georgetown-Lombardi Comprehensive Cancer Center

Washington D.C., District of Columbia, 20007, United States
Memorial Sloan Kettering Nassau

New York, New York, 11065, United States
Yale University School Of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.